Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Cytokine. 2024 Jul;179:156636. doi: 10.1016/j.cyto.2024.156636. Epub 2024 May 7.
Interleukin-2 (IL-2) is one of the most important cytokines that regulate the activation and proliferation of T cells and natural killer cells. The production of IL-2 may be affected by polymorphisms in the promoter region of the IL-2 gene (rs2069762). In allogeneic hematopoietic cell transplantation (HCT) from adult donors, rs2069762 has been associated with the incidence of acute and chronic graft-versus-host disease (GVHD). However, the impacts of IL-2 polymorphism on cord blood transplantation (CBT) outcomes remain unclear.
The objective of this study was to assess the impact of IL-2 polymorphism rs2069762 on transplant outcomes, such as hematopoietic recovery, GVHD, overall survival, relapse, and non-relapse mortality (NRM) after CBT.
We conducted a retrospective analysis of data from adult patients who underwent single-unit CBT at our institution from November 2005 to March 2023 for whom DNA samples from recipients and donors were available. IL-2 genotyping was performed using real-time polymerase chain reaction with the TaqMan® SNP genotyping assay for rs2069762.
A total of 143 recipient and donor pairs were included in this study. The proportion of recipient IL-2 polymorphism rs2069762 was 48 % (n = 69) for AA, 42 % (n = 60) for CA, and 10 % (n = 14) for CC. The proportion of donor IL-2 polymorphism rs2069762 was 43 % (n = 61) for AA, 48 % (n = 69) for CA, and 9 % (n = 13) for CC. In the multivariate analysis, the use of an rs2069762 CA + CC donor was associated with lower neutrophil recovery compared to an rs2069762 AA donor (hazard ratio [HR], 0.66; 95 % confidence interval [CI], 0.50-0.88; P = 0.004). Furthermore, recipients of rs2069762 CA + CC were associated with higher NRM compared to recipients of rs2069762 AA (HR, 2.32; 95 % CI, 1.01-5.34; P = 0.047). Serum IL-2 levels at 8 weeks were significantly higher in rs2069762 CA + CC recipients compared to those with rs2069762 AA recipients (P = 0.014).
Our data showed that donor IL-2 polymorphism affects neutrophil recovery and recipient IL-2 polymorphism affects NRM in adults undergoing single-unit CBT. The polymorphism of IL-2 rs2069762 in recipients and donors might be associated with the clinical outcomes of single-unit CBT.
白细胞介素-2 (IL-2) 是调节 T 细胞和自然杀伤细胞激活和增殖的最重要细胞因子之一。IL-2 的产生可能受到 IL-2 基因启动子区域(rs2069762)多态性的影响。在成人供体异基因造血细胞移植 (HCT) 中,rs2069762 与急性和慢性移植物抗宿主病 (GVHD) 的发生率有关。然而,IL-2 多态性对脐带血移植 (CBT) 结果的影响仍不清楚。
本研究旨在评估 IL-2 多态性 rs2069762 对移植结果的影响,如造血恢复、GVHD、总生存率、复发和非复发死亡率(NRM)。
我们对 2005 年 11 月至 2023 年 3 月在我们机构接受单份 CBT 的成人患者进行了回顾性分析,这些患者的供体和受体均有 DNA 样本。使用 TaqMan® SNP 基因分型检测试剂盒对 rs2069762 进行实时聚合酶链反应 IL-2 基因分型。
本研究共纳入 143 对受体和供体。受体 IL-2 多态性 rs2069762 的比例为 48%(n=69)为 AA,42%(n=60)为 CA,10%(n=14)为 CC。供体 IL-2 多态性 rs2069762 的比例为 43%(n=61)为 AA,48%(n=69)为 CA,9%(n=13)为 CC。多变量分析显示,与 rs2069762 AA 供体相比,rs2069762 CA+CC 供体的中性粒细胞恢复较低(风险比 [HR],0.66;95%置信区间 [CI],0.50-0.88;P=0.004)。此外,与 rs2069762 AA 受体相比,rs2069762 CA+CC 受体的 NRM 更高(HR,2.32;95%CI,1.01-5.34;P=0.047)。与 rs2069762 AA 受体相比,rs2069762 CA+CC 受体的 8 周时血清 IL-2 水平显著升高(P=0.014)。
我们的数据表明,供体 IL-2 多态性影响中性粒细胞恢复,受体 IL-2 多态性影响接受单份 CBT 的成人的 NRM。受体和供体中 IL-2 rs2069762 的多态性可能与单份 CBT 的临床结果相关。